Predicting CAR-T cell Immunotherapy Success through ImmunoPET

Alessia Volpe; Veronica L Nagle; Jason S Lewis; Vladimir Ponomarev

doi:10.1158/1078-0432.CCR-20-4297

Predicting CAR-T cell Immunotherapy Success through ImmunoPET

Clin Cancer Res. 2021 Feb 15;27(4):911-912. doi: 10.1158/1078-0432.CCR-20-4297. Epub 2020 Dec 16.

Authors

Alessia Volpe¹, Veronica L Nagle², Jason S Lewis^{1

2

3}, Vladimir Ponomarev^{4

2

3}

Affiliations

¹ Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
² Weill Cornell Medical College, New York, New York.
³ Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
⁴ Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York. ponomarv@mskcc.org.

Abstract

Chimeric antigen receptor (CAR)-T cell therapy has generated unprecedented advances in the treatment of hematologic cancers, but readily translatable imaging approaches to visualize the in vivo dynamics of CAR-T cells are lacking. Noninvasive PET imaging is the ideal tool to monitor CAR-T cells.See related article by Simonetta et al., p. 1058.

Publication types

Research Support, N.I.H., Extramural
Comment

MeSH terms

Hematologic Neoplasms*
Humans
Immunotherapy
Immunotherapy, Adoptive
Receptors, Chimeric Antigen* / genetics
T-Lymphocytes

Substances

Receptors, Chimeric Antigen

Abstract

Publication types

MeSH terms

Substances

Grants and funding